Introduction
Biotechnology innovations frequently involve nucleotide and amino acid sequences that form the foundation of new pharmaceuticals, vaccines, diagnostic methods, genetically engineered organisms, therapeutic proteins and molecular biology technologies. When these biological sequences are disclosed in a patent application, they must be presented in a standardized format to facilitate examination, prior art searches and international harmonization.
In Singapore, the Intellectual Property Office of Singapore (IPOS) requires patent applications containing nucleotide or amino acid sequences to comply with internationally recognized sequence listing standards. Since 1 July 2022, applications filed with IPOS that disclose biological sequences must include a sequence listing prepared in accordance with WIPO Standard ST.26, replacing the older ST.25 standard. This aligns Singapore’s patent filing requirements with the global framework adopted under the Patent Cooperation Treaty (PCT), improving consistency across participating patent offices.
For biotechnology companies, pharmaceutical manufacturers, universities, research institutions and patent professionals, understanding IPOS sequence listing requirements is essential. Failure to submit a compliant sequence listing may result in formal objections, examination delays, or the need for corrective filings.
This article provides a detailed overview of IPOS sequence listing requirements, explains the transition to WIPO Standard ST.26 and outlines practical considerations for filing biotechnology patent applications in Singapore.
What Is a Sequence Listing?
A sequence listing is a standardized presentation of nucleotide and amino acid sequence information disclosed in a patent application.
It enables patent examiners to:
- Identify biological sequences accurately.
- Conduct efficient prior art searches.
- Compare disclosed sequences with existing databases.
- Evaluate novelty and inventive step.
- Ensure consistency among international patent applications.
Rather than embedding lengthy sequence data throughout the specification, applicants submit the information in a structured format that can be processed electronically.
Why Sequence Listings Matter
Biotechnology inventions often rely on precise biological sequences that define the scope of the invention.
Examples include:
- DNA sequences.
- RNA sequences.
- Messenger RNA (mRNA).
- Complementary DNA (cDNA).
- Protein sequences.
- Peptides.
- Engineered enzymes.
- Gene-editing constructs.
- Synthetic biological molecules.
- Recombinant proteins.
Without standardized formatting, comparing biological inventions across patent databases would be significantly more difficult.
IPOS and International Harmonization
Singapore actively aligns its patent procedures with international standards to facilitate global patent protection.
IPOS follows internationally accepted practices established by:
- The Patent Cooperation Treaty (PCT).
- The World Intellectual Property Organization (WIPO).
- International sequence listing standards.
This harmonization reduces administrative complexity for applicants seeking patent protection in multiple jurisdictions.
Transition from ST.25 to ST.26
For many years, patent offices accepted sequence listings prepared under WIPO Standard ST.25.
However, advances in biotechnology created the need for a more comprehensive and machine-readable standard.
As a result:
- ST.25 was replaced by ST.26.
- Singapore adopted ST.26 for patent applications filed on or after 1 July 2022.
- ST.26 requires sequence listings to be submitted in XML format with standardized data fields.
The transition improves interoperability among patent offices and supports automated validation and searching.
WIPO Standard ST.26 Explained
WIPO Standard ST.26 establishes a uniform format for presenting nucleotide and amino acid sequence listings.
Key characteristics include:
- XML-based structure.
- Standardized data fields.
- Improved machine readability.
- Consistent sequence annotation.
- Enhanced search compatibility.
- Support for electronic filing.
Compared with ST.25, ST.26 captures additional information about sequence features while improving consistency across jurisdictions.
When Is a Sequence Listing Required?
A sequence listing is generally required whenever a patent application discloses nucleotide or amino acid sequences that fall within the scope of the applicable WIPO standard.
Typical biotechnology inventions requiring sequence listings include:
- Gene therapies.
- Vaccines.
- DNA constructs.
- RNA therapeutics.
- Protein engineering.
- Monoclonal antibodies.
- Diagnostic biomarkers.
- Recombinant microorganisms.
- CRISPR-based technologies.
- Synthetic biology inventions.
Applicants should carefully assess whether the disclosed biological material triggers the sequence listing requirement.
Filing Requirements Under IPOS
Where a patent application discloses a sequence, the description must include a sequence listing presented as a separate part of the description. For applications filed on or after 1 July 2022, the sequence listing must comply with WIPO Standard ST.26 and be submitted electronically through the prescribed filing process.
The sequence listing is not simply an attachmentâit forms part of the patent specification when filed as the specification sequence listing.
Sequence Listing as Part of the Specification
If the applicant intends the sequence listing to form part of the patent specification, it should be filed using the document type designated for “Sequence Listing (Specification).” This listing becomes part of the application as filed.
Sequence Listing for Search Purposes
In some circumstances, applicants may also provide a “Sequence Listing (For Reference Only)” to facilitate searching. IPOS requires such a submission to be accompanied by a declaration confirming that the information is identical to the sequence listing forming part of the application filed.
This distinction helps ensure that the official disclosure remains separate from reference material used during examination.
Importance of Filing the Sequence Listing at the Filing Date
Applicants should ensure that any sequence listing intended to form part of the invention’s disclosure is included with the application at the filing date. Under IPOS practice, a sequence listing omitted from the description at filing does not become part of the application simply because it is submitted later.
Accordingly, careful preparation before filing is essential to preserve the completeness of the disclosure.
Electronic Filing Requirements
IPOS requires electronic submission of sequence listings in accordance with its Digital Hub Practice Directions.
Electronic filing supports:
- Automated validation.
- Efficient examination.
- Improved search functionality.
- Reduced processing errors.
- International compatibility.
Applicants should verify that the XML file conforms to ST.26 before submission.
Preparing an ST.26 Sequence Listing
Preparation generally involves:
- Identifying all relevant nucleotide and amino acid sequences.
- Formatting the data using the ST.26 XML structure.
- Completing mandatory descriptive fields.
- Validating the XML file with appropriate software.
- Reviewing consistency with the patent specification.
- Submitting the validated file through the IPOS filing system.
Accuracy at this stage helps minimize formal objections during examination.
Common Information Included in ST.26 Listings
An ST.26 sequence listing may include:
- Sequence identifiers.
- Molecule type.
- Sequence length.
- Organism information where applicable.
- Feature annotations.
- Sequence descriptions.
- Nucleotide data.
- Amino acid data.
The XML format ensures these elements are organized in a standardized manner.
Validation Before Filing
Validation is a critical step in sequence listing preparation.
Applicants should confirm that:
- XML formatting is correct.
- Mandatory fields are complete.
- Sequence identifiers are consistent.
- No formatting errors exist.
- The sequence listing matches the written specification.
- File integrity has been verified.
Early validation reduces the likelihood of procedural deficiencies.
Amendments and Corrections
If corrections or amendments to a sequence listing become necessary, they must continue to comply with the prevailing WIPO Standard. IPOS also expects amendments to be clearly identified and explained in an accompanying letter.
Applicants should avoid introducing new technical subject matter through amendments, as this may affect the application under patent law.
Common Filing Mistakes
Frequent issues encountered during biotechnology patent filings include:
- Submitting an incorrect XML file.
- Omitting required sequences.
- Inconsistencies between the specification and the sequence listing.
- Failure to validate the sequence listing.
- Incorrect document type selection during filing.
- Formatting errors.
- Missing mandatory annotations.
- Inadequate review before submission.
Careful quality control can significantly reduce these risks.
Best Practices for Biotech Patent Applicants
To improve filing quality and efficiency:
- Prepare sequence listings early in the drafting process.
- Use software designed for ST.26-compliant XML generation.
- Verify consistency between claims, description and sequence data.
- Conduct technical and legal reviews before filing.
- Validate the XML file before submission.
- Maintain version control throughout drafting.
- Retain records of all validation reports and filing documents.
- Coordinate closely with inventors and patent counsel.
These practices help reduce delays and improve compliance.
Benefits of ST.26 Compliance
Adhering to ST.26 requirements provides several advantages:
- Improved examination efficiency.
- Better international consistency.
- Enhanced electronic searching.
- Reduced formatting discrepancies across jurisdictions.
- Greater compatibility with PCT procedures.
- Streamlined patent prosecution.
For applicants pursuing global patent protection, standardized sequence listings simplify multi-jurisdictional filing strategies.
Conclusion
Biotechnology patent applications often depend on the accurate disclosure of nucleotide and amino acid sequences. Singapore’s adoption of WIPO Standard ST.26 reflects a broader international move toward harmonized, machine-readable sequence listings that support efficient examination and global patent administration.
For applications filed with IPOS, sequence listings must be carefully prepared, submitted in the prescribed electronic format and, when intended to form part of the disclosure, included as a separate part of the specification at the time of filing. Proper validation, consistency with the written specification and adherence to IPOS procedural requirements can help applicants avoid formal objections and unnecessary delays.
As biotechnology innovation continues to accelerate, mastering sequence listing requirements has become an essential aspect of patent preparation. By integrating robust drafting practices with ST.26-compliant workflows, innovators and patent professionals can strengthen the quality of their applications and facilitate smoother prosecution in Singapore and other participating jurisdictions.